Version history

{
  "session_id": "sess_SDA-2026-04-13-gap-pubmed-20260410-173032-9318ca0d",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"hypothesis_id\": \"H1\",\n      \"title\": \"PSEN2 Loss-of-Function Impairs TFEB-Mediated Autophagic Clearance of α-Synuclein\",\n      \"target_genes\": [\"TFEB\", \"TRPML1\", \"MTOR\"],\n      \"composite_score\": 0.62,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.75,\n        \"evidence_strength\": 0.58,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.65,\n        \"therapeutic_potential\": 0.72,\n        \"druggability\": 0.52,\n        \"safety_profile\": 0.45,\n        \"competitive_landscape\": 0.75,\n        \"data_availability\": 0.62,\n        \"reproducibility\": 0.65\n      },\n      \"evidence_for\": [\n        {\"claim\": \"PSEN2 physically interacts with and regulates lysosomal calcium channels\", \"pmid\": \"28581057\"},\n        {\"claim\": \"TFEB overexpression clears αS aggregates in cellular models\", \"pmid\": \"30104625\"},\n        {\"claim\": \"Lysosomal dysfunction is a shared feature of PSEN2 and αS pathology\", \"pmid\": \"30772822\"},\n        {\"claim\": \"Autophagy-lysosome axis is robustly implicated in synucleinopathies independent of PSEN2 mechanism\", \"pmid\": \"EXPERT_SYNTHESIS\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"PSEN1, not PSEN2, is the primary driver of lysosomal dysfunction in FAD; PSEN1 is predominant catalytic subunit in neurons\", \"pmid\": \"23123218\"},\n        {\"claim\": \"TFEB activation has failed in clinical trials (trehalose failed Phase II/III for ALS and MSA)\", \"pmid\": \"31705244\"},\n        {\"claim\": \"PSEN2-specific contribution to TRPML1 trafficking remains poorly defined\", \"pmid\": \"SKEPTIC_REVISION\"},\n        {\"claim\": \"TFEB overexpression studies use supraphysiological levels; therapeutic relevance at endogenous expression unproven\", \"pmid\": \"SKEPTIC_REVISION\"}\n      ],\n      \"knowledge_edges\": [\n        {\"source\": \"PSEN2\", \"relation\": \"regulates\", \"target\": \"TRPML1\", \"edge_type\": \"protein-protein_interaction\", \"pmid\": \"28581057\"},\n        {\"source\": \"TRPML1\", \"relation\": \"activates\", \"target\": \"lysosomal_calcium_release\", \"edge_type\": \"functional\"},\n        {\"source\": \"mTORC1\", \"relation\": \"phosphorylates\", \"target\": \"TFEB\", \"edge_type\": \"post_translational\", \"pmid\": \"SKEPTIC_REVISION\"},\n        {\"source\": \"TFEB\", \"relation\": \"translocates_to_nucleus\", \"target\": \"CLEAR_gene_network\", \"edge_type\": \"transcriptional\"},\n        {\"source\": \"TFEB\", \"relation\": \"upregulates\", \"target\": \"autophagy_lysosome_genes\", \"edge_type\": \"transcriptional\", \"pmid\": \"30104625\"},\n        {\"source\": \"autophagy_lysosome\", \"relation\": \"degrades\", \"target\": \"alpha_synuclein\", \"edge_type\": \"functional\", \"pmid\": \"30772822\"}\n      ],\n      \"synthesis_notes\": \"Despite PSEN1/PSEN2 specificity concerns, this remains the most therapeutically actionable hypothesis. TFEB activation bypasses direct PSEN2 manipulation. Trehalose failure was likely due to inadequate CNS penetration rather than target invalidation. Requires: (1) confirm PSEN2-specific TRPML1 axis in human neurons, (2) demonstrate TFEB nuclear translocation impairment at endogenous levels.\"\n    },\n    {\n      \"rank\": 2,\n      \"hypothesis_id\": \"H6\",\n      \"title\": \"PSEN2 Mutations Drive p38 MAPK-Mediated Phosphorylation of SNCA at S129 via Sustained Oxidative Stress\",\n      \"target_genes\": [\"MAPK14\", \"MAP2K3\", \"MAP2K6\", \"SNCA\"],\n      \"composite_score\": 0.54,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.68,\n        \"evidence_strength\": 0.52,\n        \"novelty\": 0.50,\n        \"feasibility\": 0.45,\n        \"therapeutic_potential\": 0.55,\n        \"druggability\": 0.58,\n        \"safety_profile\": 0.35,\n        \"competitive_landscape\": 0.60,\n        \"data_availability\": 0.55,\n        \"reproducibility\": 0.52\n      },\n      \"evidence_for\": [\n        {\"claim\": \"PSEN2 mutations cause mitochondrial ROS elevation\", \"pmid\": \"23430502\"},\n        {\"claim\": \"p38 MAPK phosphorylates SNCA at S129 and promotes aggregation\", \"pmid\": \"12538644\"},\n        {\"claim\": \"Oxidative stress is sufficient to drive SNCA phosphorylation via p38\", \"pmid\": \"12538644\"},\n        {\"claim\": \"p38 inhibitors reduce SNCA pathology in vivo\", \"pmid\": \"21868389\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"p38 inhibitors have failed clinically for cardiovascular and inflammatory diseases; CNS penetration is major challenge\", \"pmid\": \"EXPERT_ASSESSMENT\"},\n        {\"claim\": \"Multiple kinases phosphorylate S129 (CK1, CK2, PLK2/3, GRKs); p38 is one of several\", \"pmid\": \"12534373\"},\n        {\"claim\": \"S129 phosphorylation may be protective as it promotes αS degradation\", \"pmid\": \"19010788\"},\n        {\"claim\": \"Mitochondrial ROS in PSEN2 mutations is variable; not all mutations cause dramatic ROS\", \"pmid\": \"SKEPTIC_REVISION\"}\n      ],\n      \"knowledge_edges\": [\n        {\"source\": \"PSEN2_mutations\", \"relation\": \"causes\", \"target\": \"mitochondrial_dysfunction\", \"edge_type\": \"functional\", \"pmid\": \"23430502\"},\n        {\"source\": \"mitochondrial_dysfunction\", \"relation\": \"produces\", \"target\": \"ROS\", \"edge_type\": \"metabolic\"},\n        {\"source\": \"ROS\", \"relation\": \"activates\", \"target\": \"MAPK14\", \"edge_type\": \"post_translational\", \"pmid\": \"12538644\"},\n        {\"source\": \"MAPK14\", \"relation\": \"phosphorylates\", \"target\": \"SNCA_S129\", \"edge_type\": \"catalytic\", \"pmid\": \"12538644\"},\n        {\"source\": \"MAP2K3_MAP2K6\", \"relation\": \"phosphorylates\", \"target\": \"MAPK14\", \"edge_type\": \"catalytic\"},\n        {\"source\": \"SNCA_S129_phosphorylation\", \"relation\": \"promotes\", \"target\": \"alpha_synuclein_aggregation\", \"edge_type\": \"functional\", \"pmid\": \"21868389\"}\n      ],\n      \"synthesis_notes\": \"Mechanistically coherent but therapeutically risky given p38 inhibitor history. Alternative strategy: target upstream MAPKKK (MAP2K3/6) for more selective pathway blockade. CK1δ as S129 kinase may be more tractable with CNS-penetrant compounds (e.g., LH-846). Requires: (1) p38α neuronal KO in PSEN2 mutant mice, (2) direct ROS measurement correlation with p38 activity.\"\n    },\n    {\n      \"rank\": 3,\n      \"hypothesis_id\": \"H3\",\n      \"title\": \"PSEN2-Dependent Calcium Dysregulation Activates Calcineurin/NFAT Signaling to Drive SNCA Transcription\",\n      \"target_genes\": [\"PPP3CA\", \"NFATC3\", \"CALM1\", \"STIM1\", \"ORAI1\"],\n      \"composite_score\": 0.48,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.52,\n        \"evidence_strength\": 0.40,\n        \"novelty\": 0.60,\n        \"feasibility\": 0.48,\n        \"therapeutic_potential\": 0.42,\n        \"druggability\": 0.72,\n        \"safety_profile\": 0.28,\n        \"competitive_landscape\": 0.45,\n        \"data_availability\": 0.38,\n        \"reproducibility\": 0.52\n      },\n      \"evidence_for\": [\n        {\"claim\": \"PSEN2 mutations disrupt ER calcium homeostasis and SOCE\", \"pmid\": \"12697763\"},\n        {\"claim\": \"Calcineurin-NFAT signaling regulates SNCA transcription\", \"pmid\": \"18323783\"},\n        {\"claim\": \"NFAT activation is sufficient to increase αS mRNA\", \"pmid\": \"18323783\"},\n        {\"claim\": \"Calcineurin inhibitors reduce SNCA expression in cells\", \"pmid\": \"18323783\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Calcineurin-NFAT evidence is limited to non-neuronal cells; neuronal calcium compartments differ\", \"pmid\": \"SKEPTIC_REVISION\"},\n        {\"claim\": \"NFAT is largely inactive in mature neurons; CaMKII/CREB pathways are preferred\", \"pmid\": \"19240042\"},\n        {\"claim\": \"Calcineurin inhibitors (cyclosporine, FK506) have failed in PD trials with negative results\", \"pmid\": \"EXPERT_ASSESSMENT\"},\n        {\"claim\": \"SNCA transcriptional regulation is predominantly via NRF2/PGC-1α, not NFAT\", \"pmid\": \"SKEPTIC_REVISION\"}\n      ],\n      \"knowledge_edges\": [\n        {\"source\": \"PSEN2_mutations\", \"relation\": \"disrupts\", \"target\": \"ER_calcium\", \"edge_type\": \"functional\", \"pmid\": \"12697763\"},\n        {\"source\": \"ER_calcium_depletion\", \"relation\": \"activates\", \"target\": \"SOCE\", \"edge_type\": \"physiological\"},\n        {\"source\": \"SOCE\", \"relation\": \"increases\", \"target\": \"cytosolic_calcium\", \"edge_type\": \"metabolic\"},\n        {\"source\": \"cytosolic_calcium\", \"relation\": \"activates\", \"target\": \"PPP3CA\", \"edge_type\": \"post_translational\", \"pmid\": \"18323783\"},\n        {\"source\": \"PPP3CA\", \"relation\": \"dephosphorylates\", \"target\": \"NFATC3\", \"edge_type\": \"catalytic\", \"pmid\": \"18323783\"},\n        {\"source\": \"NFATC3\", \"relation\": \"translocates_to_nucleus\", \"target\": \"SNCA_promoter\", \"edge_type\": \"transcriptional\"},\n        {\"source\": \"NFATC3\", \"relation\": \"activates_transcription\", \"target\": \"SNCA\", \"edge_type\": \"transcriptional\", \"pmid\": \"18323783\"}\n      ],\n      \"synthesis_notes\": \"Druggable target (calcineurin is well-characterized) but existing inhibitors (cyclosporine, FK506) are too toxic for chronic neurodegeneration use. Fundamental rescue data in neurons required before investment. Key experiments: NFAT ChIP-seq in PSEN2 mutant neurons, calcineurin shRNA bidirectionality test.\"\n    },\n    {\n      \"rank\": 4,\n      \"hypothesis_id\": \"H7\",\n      \"title\": \"PSEN2 Acts as a Scaffold for LRRK2 G2019S Kinase Activity Toward RAB Proteins, and PSEN2 Loss Disinhibits Rab35-Dependent α-Synuclein Aggregation\",\n      \"target_genes\": [\"LRRK2\", \"RAB35\", \"RAB8A\", \"RAB10\", \"RAB12\"],\n      \"composite_score\": 0.46,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.48,\n        \"evidence_strength\": 0.45,\n        \"novelty\": 0.72,\n        \"feasibility\": 0.42,\n        \"therapeutic_potential\": 0.52,\n        \"druggability\": 0.55,\n        \"safety_profile\": 0.40,\n        \"competitive_landscape\": 0.48,\n        \"data_availability\": 0.40,\n        \"reproducibility\": 0.42\n      },\n      \"evidence_for\": [\n        {\"claim\": \"PSEN2 interacts with LRRK2 in neurons and regulates its localization\", \"pmid\": \"29082215\"},\n        {\"claim\": \"LRRK2 phosphorylates RAB35 and RAB8A at serines targeted by Parkinson's mutations\", \"pmid\": \"26680790\"},\n        {\"claim\": \"RAB35 knockdown causes SNCA accumulation in neurons\", \"pmid\": \"28771167\"},\n        {\"claim\": \"LRRK2 G2019S increases SNCA aggregation in neurons\", \"pmid\": \"24430582\"},\n        {\"claim\": \"PSEN2, LRRK2, and SNCA form a genetic risk network in PD\", \"pmid\": \"29082215\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"PSEN2 as scaffold for LRRK2 is novel and unproven; PSEN2 lacks typical scaffold domains\", \"pmid\": \"SKEPTIC_REVISION\"},\n        {\"claim\": \"RAB35 is not a major LRRK2 substrate; lower phosphorylation stoichiometry than RAB8/10/12\", \"pmid\": \"SKEPTIC_REVISION\"},\n        {\"claim\": \"LRRK2 G2019S is gain-of-function; PSEN2 mutations are typically loss-of-function—mechanistically opposite\", \"pmid\": \"SKEPTIC_REVISION\"},\n        {\"claim\": \"RAB35 knockdown phenotypes are modest compared to other RABs\", \"pmid\": \"SKEPTIC_REVISION\"}\n      ],\n      \"knowledge_edges\": [\n        {\"source\": \"PSEN2\", \"relation\": \"interacts_with\", \"target\": \"LRRK2\", \"edge_type\": \"protein-protein_interaction\", \"pmid\": \"29082215\"},\n        {\"source\": \"PSEN2\", \"relation\": \"may_scaffold\", \"target\": \"LRRK2_kinase_activity\", \"edge_type\": \"hypothetical\"},\n        {\"source\": \"LRRK2\", \"relation\": \"phosphorylates\", \"target\": \"RAB35\", \"edge_type\": \"catalytic\", \"pmid\": \"26680790\"},\n        {\"source\": \"LRRK2\", \"relation\": \"phosphorylates\", \"target\": \"RAB8A_RAB10_RAB12\", \"edge_type\": \"catalytic\", \"pmid\": \"26680790\"},\n        {\"source\": \"RAB35\", \"relation\": \"regulates\", \"target\": \"endosomal_recycling\", \"edge_type\": \"functional\", \"pmid\": \"28771167\"},\n        {\"source\": \"endosomal_recycling\", \"relation\": \" traffics\", \"target\": \"SNCA\", \"edge_type\": \"functional\"},\n        {\"source\": \"RAB35_deficiency\", \"relation\": \"causes\", \"target\": \"SNCA_accumulation\", \"edge_type\": \"functional\", \"pmid\": \"28771167\"},\n        {\"source\": \"LRRK2_G2019S\", \"relation\": \"increases\", \"target\": \"SNCA_aggregation\", \"edge_type\": \"functional\", \"pmid\": \"24430582\"}\n      ],\n      \"synthesis_notes\": \"Leverages existing LRRK2 inhibitor programs (DNL151/BIIB122 in Phase I/II). However, scaffold hypothesis requires validation before investment. Key: establish whether PSEN2-LRRK2 interaction is necessary for RAB35 phosphorylation. Direct RAB35 modulators essentially nonexistent as chemical matter.\"\n    },\n    {\n      \"rank\": 5,\n      \"hypothesis_id\": \"H4\",\n      \"title\": \"β-Amyloid-Actin-PSEN2 Module Regulates Synaptic Vesicle Trafficking of α-Synuclein for Exosomal Secretion\",\n      \"target_genes\": [\"ACTB\", \"ACTG1\", \"RAB27A\", \"APP\"],\n      \"composite_score\": 0.44,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.45,\n        \"evidence_strength\": 0.38,\n        \"novelty\": 0.68,\n        \"feasibility\": 0.35,\n        \"therapeutic_potential\": 0.48,\n        \"druggability\": 0.42,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.52,\n        \"data_availability\": 0.32,\n        \"reproducibility\": 0.30\n      },\n      \"evidence_for\": [\n        {\"claim\": \"β-amyloid oligomers cause actin cytoskeleton remodeling\", \"pmid\": \"25425364\"},\n        {\"claim\": \"αS is trafficked via synaptic vesicles and secreted via exosomes\", \"pmid\": \"23792770\"},\n        {\"claim\": \"Actin polymerization regulates exosome release\", \"pmid\": \"28655760\"},\n        {\"claim\": \"PSEN2 regulates presynaptic function and vesicle trafficking\", \"pmid\": \"26040716\"},\n        {\"claim\": \"Preprint identifies β-amyloid-actin-PSEN2 as shared genetic risk module\", \"pmid\": \"38496508\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Foundational preprint (PMID:38496508) has not undergone peer review\", \"pmid\": \"SKEPTIC_REVISION\"},\n        {\"claim\": \"PSEN2 mutations often reduce Aβ production (loss-of-function), contradicting model\", \"pmid\": \"11483623\"},\n        {\"claim\": \"PSEN2 is primarily endosomal/lysosomal, not presynaptic\", \"pmid\": \"SKEPTIC_REVISION\"},\n        {\"claim\": \"Exosomal αS secretion is a minority pathway; most αS release is via unconventional secretion\", \"pmid\": \"SKEPTIC_REVISION\"}\n      ],\n      \"knowledge_edges\": [\n        {\"source\": \"PSEN2\", \"relation\": \"generates\", \"target\": \"beta_amyloid\", \"edge_type\": \"catalytic\"},\n        {\"source\": \"beta_amyloid_oligomers\", \"relation\": \"remodels\", \"target\": \"actin_cytoskeleton\", \"edge_type\": \"functional\", \"pmid\": \"25425364\"},\n        {\"source\": \"actin_cytoskeleton\", \"relation\": \"regulates\", \"target\": \"exosome_release\", \"edge_type\": \"functional\", \"pmid\": \"28655760\"},\n        {\"source\": \"alpha_synuclein\", \"relation\": \"localizes_to\", \"target\": \"synaptic_vesicles\", \"edge_type\": \"subcellular\", \"pmid\": \"23792770\"},\n        {\"source\": \"alpha_synuclein\", \"relation\": \"packaged_into\", \"target\": \"exosomes\", \"edge_type\": \"vesicular\", \"pmid\": \"23792770\"},\n        {\"source\": \"RAB27A\", \"relation\": \"regulates\", \"target\": \"exosome_secretion\", \"edge_type\": \"functional\"},\n        {\"source\": \"beta_amyloid\", \"relation\": \"modifies\", \"target\": \"alpha_synuclein_vesicular_trafficking\", \"edge_type\": \"hypothetical\"}\n      ],\n      \"synthesis_notes\": \"Highest risk due to preprint foundation. If validated, RAB27A is most druggable node (small molecule RAB27A modulators exist in oncology literature). β-amyloid neutralization with existing antibodies (BAN2401, Lecanemab) targets extracellular Aβ, not intracellular exosomal pathway. Do not advance without preprint replication.\"\n    },\n    {\n      \"rank\": 6,\n      \"hypothesis_id\": \"H2\",\n      \"title\": \"PSEN2/γ-Secretase Generates C-Terminal APP Fragments that Transcriptionally Repress SNCA via AP-1 Complex\",\n      \"target_genes\": [\"APP\", \"APBB1\", \"KAT2B\", \"SNCA\"],\n      \"composite_score\": 0.38,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.32,\n        \"evidence_strength\": 0.30,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.25,\n        \"therapeutic_potential\": 0.35,\n        \"druggability\": 0.22,\n        \"safety_profile\": 0.30,\n        \"competitive_landscape\": 0.45,\n        \"data_availability\": 0.35,\n        \"reproducibility\": 0.28\n      },\n      \"evidence_for\": [\n        {\"claim\": \"AICD functions as a transcriptional regulator with Fe65/Tip60\", \"pmid\": \"11919187\"},\n        {\"claim\": \"PSEN2 mutations alter APP processing and AICD generation\", \"pmid\": \"10771098\"},\n        {\"claim\": \"APP and SNCA share transcriptional regulatory elements\", \"pmid\": \"19029302\"},\n        {\"claim\": \"PSEN2 localizes to the nucleus in neurons\", \"pmid\": \"16289421\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"AICD transcriptional targets are highly disputed; genome-wide studies fail to consistently identify SNCA\", \"pmid\": \"20448178\"},\n        {\"claim\": \"PSEN2 mutations do not universally increase SNCA expression; some show decreased SNCA\", \"pmid\": \"SKEPTIC_REVISION\"},\n        {\"claim\": \"AICD is transient and rapidly degraded; difficult to detect under physiological conditions\", \"pmid\": \"SKEPTIC_REVISION\"},\n        {\"claim\": \"Fe65/Tip60 complexes prefer other transcription factors (LRP1) over AICD\", \"pmid\": \"SKEPTIC_REVISION\"}\n      ],\n      \"knowledge_edges\": [\n        {\"source\": \"PSEN2\", \"relation\": \"catalyzes\", \"target\": \"gamma_secretase_cleavage\", \"edge_type\": \"catalytic\"},\n        {\"source\": \"APP\", \"relation\": \"cleaved_by\", \"target\": \"gamma_secretase\", \"edge_type\": \"catalytic\"},\n        {\"source\": \"gamma_secretase\", \"relation\": \"generates\", \"target\": \"AICD\", \"edge_type\": \"catalytic\", \"pmid\": \"10771098\"},\n        {\"source\": \"AICD\", \"relation\": \"forms_complex_with\", \"target\": \"FE65_KAT2B\", \"edge_type\": \"protein-protein_interaction\", \"pmid\": \"11919187\"},\n        {\"source\": \"AICD_complex\", \"relation\": \"binds_to\", \"target\": \"AP1_sites\", \"edge_type\": \"DNA-binding\", \"pmid\": \"19029302\"},\n        {\"source\": \"AICD_complex\", \"relation\": \"may_repress\", \"target\": \"SNCA_promoter\", \"edge_type\": \"hypothetical_transcriptional\"}\n      ],\n      \"synthesis_notes\": \"Not pharmacologically tractable. AICD is transient, not a viable small molecule target. No pharmacological tool to selectively modulate nuclear AICD exists. Deprioritize; pursue only if mechanistic validation shows SNCA as direct AICD target in human neurons.\"\n    },\n    {\n      \"rank\": 7,\n      \"hypothesis_id\": \"H5\",\n      \"title\": \"PSEN2 Regulates ER-Associated Degradation (ERAD) of Newly Synthesized α-Synuclein at the ER Membrane\",\n      \"target_genes\": [\"SEL1L\", \"HMGCR\", \"DERL1\", \"VCP\"],\n      \"composite_score\": 0.35,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.28,\n        \"evidence_strength\": 0.32,\n        \"novelty\": 0.52,\n        \"feasibility\": 0.30,\n        \"therapeutic_potential\": 0.38,\n        \"druggability\": 0.45,\n        \"safety_profile\": 0.38,\n        \"competitive_landscape\": 0.35,\n        \"data_availability\": 0.30,\n        \"reproducibility\": 0.32\n      },\n      \"evidence_for\": [\n        {\"claim\": \"PSEN2 physically associates with ERAD components\", \"pmid\": \"21782406\"},\n        {\"claim\": \"αS interacts with ER-resident chaperones and undergoes quality control\", \"pmid\": \"24445457\"},\n        {\"claim\": \"ERAD impairment causes αS accumulation at ER/Golgi\", \"pmid\": \"24445457\"},\n        {\"claim\": \"XBP1s enhances ERAD and reduces αS aggregation\", \"pmid\": \"20685960\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"αS is not a classic ERAD substrate; synthesized on free ribosomes, does not enter secretory pathway\", \"pmid\": \"SKEPTIC_REVISION\"},\n        {\"claim\": \"αS degradation is primarily cytosolic via UPS and autophagy; ERAD components not implicated\", \"pmid\": \"SKEPTIC_REVISION\"},\n        {\"claim\": \"PSEN2-ERAD evidence is circumstantial; physical association does not establish functional pathway\", \"pmid\": \"SKEPTIC_REVISION\"},\n        {\"claim\": \"Loss of PSEN2 does not cause general ERAD failure; effect appears specific to APP\", \"pmid\": \"SKEPTIC_REVISION\"}\n      ],\n      \"knowledge_edges\": [\n        {\"source\": \"PSEN2\", \"relation\": \"associates_with\", \"target\": \"DERL1\", \"edge_type\": \"protein-protein_interaction\", \"pmid\": \"21782406\"},\n        {\"source\": \"PSEN2\", \"relation\": \"associates_with\", \"target\": \"SEL1L_HRD1\", \"edge_type\": \"protein-protein_interaction\", \"pmid\": \"21782406\"},\n        {\"source\": \"alpha_synuclein\", \"relation\": \"may_interact_with\", \"target\": \"ER_chaperones\", \"edge_type\": \"speculative\", \"pmid\": \"24445457\"},\n        {\"source\": \"ERAD_complex\", \"relation\": \"may_retrotranslocate\", \"target\": \"nascent_alpha_synuclein\", \"edge_type\": \"speculative\"},\n        {\"source\": \"XBP1s\", \"relation\": \"enhances\", \"target\": \"ERAD\", \"edge_type\": \"functional\", \"pmid\": \"20685960\"},\n        {\"source\": \"XBP1s\", \"relation\": \"reduces\", \"target\": \"alpha_synuclein_aggregation\", \"edge_type\": \"functional\", \"pmid\": \"20685960\"}\n      ],\n      \"synthesis_notes\": \"Fundamental premise that αS is an ERAD substrate lacks strong support. ERAD enhancers exist (Geldanamycin derivatives, p97/VCP modulators) but without αS-ERAD validation, these will not work. Do not advance; requires in vitro ERAD assay with radiolabeled nascent αS to establish substrate validity.\"\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"id\": \"KE1\",\n      \"source\": \"PSEN2\",\n      \"relation\": \"regulates\",\n      \"target\": \"lysosomal_function\",\n      \"pathway\": \"autophagy\",\n      \"supporting_pmids\": [\"28581057\", \"30772822\"]\n    },\n    {\n      \"id\": \"KE2\",\n      \"source\": \"PSEN2\",\n      \"relation\": \"disrupts\",\n      \"target\": \"calcium_homeostasis\",\n      \"pathway\": \"ER_stress\",\n      \"supporting_pmids\": [\"12697763\"]\n    },\n    {\n      \"id\": \"KE3\",\n      \"source\": \"PSEN2\",\n      \"relation\": \"causes\",\n      \"target\": \"mitochondrial_dysfunction\",\n      \"pathway\": \"oxidative_stress\",\n      \"supporting_pmids\": [\"23430502\"]\n    },\n    {\n      \"id\": \"KE4\",\n      \"source\": \"PSEN2\",\n      \"relation\": \"generates\",\n      \"target\": \"beta_amyloid\",\n      \"pathway\": \"APP_processing\",\n      \"supporting_pmids\": [\"10771098\"]\n    },\n    {\n      \"id\": \"KE5\",\n      \"source\": \"PSEN2\",\n      \"relation\": \"interacts_with\",\n      \"target\": \"LRRK2\",\n      \"pathway\": \"vesicular_trafficking\",\n      \"supporting_pmids\": [\"29082215\"]\n    },\n    {\n      \"id\": \"KE6\",\n      \"source\": \"PSEN2\",\n      \"relation\": \"associates_with\",\n      \"target\": \"ERAD_components\",\n      \"pathway\": \"protein_quality_control\",\n      \"supporting_pmids\": [\"21782406\"]\n    },\n    {\n      \"id\": \"KE7\",\n      \"source\": \"TFEB\",\n      \"relation\": \"upregulates\",\n      \"target\": \"autophagy_lysosome_network\",\n      \"pathway\": \"lysosomal_biogenesis\",\n      \"supporting_pmids\": [\"30104625\"]\n    },\n    {\n      \"id\": \"KE8\",\n      \"source\": \"alpha_synuclein\",\n      \"relation\": \"accumulates_in\",\n      \"target\": \"Lewy_bodies\",\n      \"pathway\": \"synucleinopathy\",\n      \"supporting_pmids\": []\n    },\n    {\n      \"id\": \"KE9\",\n      \"source\": \"LRRK2\",\n      \"relation\": \"phosphorylates\",\n      \"target\": \"RAB_GTPases\",\n      \"pathway\": \"endosomal_trafficking\",\n      \"supporting_pmids\": [\"26680790\"]\n    },\n    {\n      \"id\": \"KE10\",\n      \"source\": \"MAPK14\",\n      \"relation\": \"phosphorylates\",\n      \"target\": \"SNCA_S129\",\n      \"pathway\": \"post_translational_modification\",\n      \"supporting_pmids\": [\"12538644\"]\n    },\n    {\n      \"id\": \"KE11\",\n      \"source\": \"beta_amyloid\",\n      \"relation\": \"remodels\",\n      \"target\": \"actin_cytoskeleton\",\n      \"pathway\": \"cytoskeletal_dynamics\",\n      \"supporting_pmids\": [\"25425364\"]\n    },\n    {\n      \"id\": \"KE12\",\n      \"source\": \"actin\",\n      \"relation\": \"regulates\",\n      \"target\": \"exosome_release\",\n      \"pathway\": \"secretory_pathway\",\n      \"supporting_pmids\": [\"28655760\"]\n    },\n    {\n      \"id\": \"KE13\",\n      \"source\": \"AICD\",\n      \"relation\": \"forms_complex\",\n      \"target\": \"FE65_KAT2B\",\n      \"pathway\": \"nuclear_signaling\",\n      \"supporting_pmids\": [\"11919187\"]\n    },\n    {\n      \"id\": \"KE14\",\n      \"source\": \"XBP1s\",\n      \"relation\": \"enhances\",\n      \"target\": \"ERAD\",\n      \"pathway\": \"unfolded_protein_response\",\n      \"supporting_pmids\": [\"20685960\"]\n    }\n  ],\n  \"top_3_for_investigation\": [\n    {\n      \"rank\": 1,\n      \"hypothesis_id\": \"H1\",\n      \"title\": \"TFEB Activation to Compensate for Lysosomal PSEN2 Defect\",\n      \"rationale\": \"Most therapeutically actionable despite PSEN1/PSEN2 specificity concerns. Autophagy-lysosome axis is established in synucleinopathies independent of PSEN2 mechanism. Trehalose failure likely due to inadequate CNS penetration. Key experiments needed: (1) Confirm PSEN2-specific TRPML1 axis in human neurons, (2) Demonstrate TFEB nuclear translocation impairment at endogenous levels vs. overexpression rescue.\",\n      \"estimated_cost\": \"$15-25M\",\n      \"estimated_timeline\": \"24-30 months to identify CNS-penetrant TFEB activator\",\n      \"priority_experiments\": [\n        \"PSEN2-specific vs PSEN1 TRPML1 contribution in human iPSC neurons\",\n        \"Endogenous TFEB nuclear translocation assay in PSEN2 mutant vs WT neurons\",\n        \"Cross-rescue: constitutively nuclear TFEB in PSEN2 mutant neurons\"\n      ]\n    },\n    {\n      \"rank\": 2,\n      \"hypothesis_id\": \"H6\",\n      \"title\": \"p38 MAPK Inhibition for PSEN2-Mediated SNCA S129 Phosphorylation\",\n      \"rationale\": \"Mechanistically coherent pathway connecting PSEN2 mutations to αS pathology through ROS-p38-S129 axis. However, p38 inhibitor history is poor. Recommend upstream MAPKKK targeting (MAP2K3/6) or CK1δ as alternative S129 kinase with better CNS tractability.\",\n      \"estimated_cost\": \"$20-30M\",\n      \"estimated_timeline\": \"18-24 months for selective CNS-penetrant inhibitor identification\",\n      \"priority_experiments\": [\n        \"p38α neuronal KO in PSEN2 mutant mice - must show behavioral rescue\",\n        \"Direct ROS measurement (MitoSOX) correlation with p38 activity\",\n        \"Compare upstream MAPKKK (MAP2K3/6) knockdown vs direct p38 inhibition\",\n        \"Evaluate CK1δ as alternative S129 kinase\"\n      ]\n    },\n    {\n      \"rank\": 3,\n      \"hypothesis_id\": \"H7\",\n      \"title\": \"PSEN2/LRRK2/Rab35 Genetic Interaction\",\n      \"rationale\": \"Leverages existing LRRK2 inhibitor programs (DNL151/BIIB122 in active clinical development for Parkinson's). Requires validation of PSEN2 as scaffold for LRRK2 kinase activity toward RAB35. If scaffold function confirmed, RAB35 stabilization or LRRK2 kinase inhibition becomes therapeutic strategy.\",\n      \"estimated_cost\": \"$30-40M (leverages existing LRRK2 programs)\",\n      \"estimated_timeline\": \"12-18 months for scaffold validation; 24 months for compound testing\",\n      \"priority_experiments\": [\n        \"PSEN2-LRRK2 binding",
  "tokens_used": "6537",
  "persona_id": "persona-synthesizer"
}